The HPV16E7 Affibody as a Novel Potential Therapeutic Agent for Treating Cervical Cancer Is Likely Internalized through Dynamin and Caveolin-1 Dependent Endocytosis.

ABSTRACT: Affibodies targeting intracellular proteins have a great potential to function as ideal therapeutic agents. However, little is known about how the affibodies enter target cells to interact with intracellular target proteins. We have previously developed the HPV16E7 affibody (Z_HPV16E7384) for HPV16 positive cervical cancer treatment. Here, we explored the underlying mechanisms of Z_HPV16E7384 and found that Z_HPV16E7384 significantly inhibited the proliferation of target cells and induced a G1/S phase cell cycle arrest. Furthermore, Z_HPV16E7384 treatment resulted in the upregulation of retinoblastoma protein (Rb) and downregulation of phosphorylated Rb (pRb), E2F1, cyclin D1, and CDK4 in the target cells. Moreover, treatment with dynamin or the cave

SUBMITTER: Zhang Q 

PROVIDER: S-EPMC9405713 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature